These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 24070418)

  • 1. Deletion of the olfactomedin 4 gene is associated with progression of human prostate cancer.
    Li H; Rodriguez-Canales J; Liu W; Zhu J; Hanson JC; Pack S; Zhuang Z; Emmert-Buck MR; Rodgers GP
    Am J Pathol; 2013 Oct; 183(4):1329-38. PubMed ID: 24070418
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Olfactomedin 4 downregulation is associated with tumor initiation, growth and progression in human prostate cancer.
    Li H; Kim C; Liu W; Zhu J; Chin K; Rodriguez-Canales J; Rodgers GP
    Int J Cancer; 2020 Mar; 146(5):1346-1358. PubMed ID: 31241767
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Olfactomedin 4 suppresses prostate cancer cell growth and metastasis via negative interaction with cathepsin D and SDF-1.
    Chen L; Li H; Liu W; Zhu J; Zhao X; Wright E; Cao L; Ding I; Rodgers GP
    Carcinogenesis; 2011 Jul; 32(7):986-94. PubMed ID: 21470957
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Olfactomedin 4 deficiency promotes prostate neoplastic progression and is associated with upregulation of the hedgehog-signaling pathway.
    Li H; Liu W; Chen W; Zhu J; Deng CX; Rodgers GP
    Sci Rep; 2015 Nov; 5():16974. PubMed ID: 26581960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Olfactomedin 4 expression and functions in innate immunity, inflammation, and cancer.
    Liu W; Rodgers GP
    Cancer Metastasis Rev; 2016 Jun; 35(2):201-12. PubMed ID: 27178440
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oestrogen receptor-mediated expression of Olfactomedin 4 regulates the progression of endometrial adenocarcinoma.
    Duan C; Liu X; Liang S; Yang Z; Xia M; Wang L; Chen S; Yu L
    J Cell Mol Med; 2014 May; 18(5):863-74. PubMed ID: 24495253
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Olfactomedin 4, a novel marker for the differentiation and progression of gastrointestinal cancers.
    Yu L; Wang L; Chen S
    Neoplasma; 2011; 58(1):9-13. PubMed ID: 21067260
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Olfactomedin 4 mediation of prostate stem/progenitor-like cell proliferation and differentiation via MYC.
    Li H; Chaitankar V; Zhu J; Chin K; Liu W; Pirooznia M; Rodgers GP
    Sci Rep; 2020 Dec; 10(1):21924. PubMed ID: 33318499
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High expression of olfactomedin-4 is correlated with chemoresistance and poor prognosis in pancreatic cancer.
    Ohkuma R; Yada E; Ishikawa S; Komura D; Ishizaki H; Tamada K; Kubota Y; Hamada K; Ishida H; Hirasawa Y; Ariizumi H; Satoh E; Shida M; Watanabe M; Onoue R; Ando K; Tsurutani J; Yoshimura K; Yokobori T; Sasada T; Aoki T; Murakami M; Norose T; Ohike N; Takimoto M; Izumizaki M; Kobayashi S; Tsunoda T; Wada S
    PLoS One; 2020; 15(1):e0226707. PubMed ID: 31923206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Depletion of OLFM4 gene inhibits cell growth and increases sensitization to hydrogen peroxide and tumor necrosis factor-alpha induced-apoptosis in gastric cancer cells.
    Liu RH; Yang MH; Xiang H; Bao LM; Yang HA; Yue LW; Jiang X; Ang N; Wu LY; Huang Y
    J Biomed Sci; 2012 Apr; 19(1):38. PubMed ID: 22471589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epigenetic silencing of olfactomedin-4 enhances gastric cancer cell invasion via activation of focal adhesion kinase signaling.
    Guo LL; He ZC; Yang CQ; Qiao PT; Yin GL
    BMB Rep; 2015 Nov; 48(11):630-5. PubMed ID: 26303970
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Olfactomedin 4 associates with expression of differentiation markers but not with properties of cancer stemness, EMT nor metastatic spread in colorectal cancer.
    Jaitner S; Pretzsch E; Neumann J; Schäffauer A; Schiemann M; Angele M; Kumbrink J; Schwitalla S; Greten FR; Brandl L; Klauschen F; Horst D; Kirchner T; Jung A
    J Pathol Clin Res; 2023 Jan; 9(1):73-85. PubMed ID: 36349502
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Olfactomedin-4 in digestive diseases: A mini-review.
    Wang XY; Chen SH; Zhang YN; Xu CF
    World J Gastroenterol; 2018 May; 24(17):1881-1887. PubMed ID: 29740203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. OLFM4 Expression in Ductal Carcinoma In Situ and in Invasive Breast Cancer Cohorts by a SWATH-Based Proteomic Approach.
    Valo I; Raro P; Boissard A; Maarouf A; Jézéquel P; Verriele V; Campone M; Coqueret O; Guette C
    Proteomics; 2019 Nov; 19(21-22):e1800446. PubMed ID: 31318138
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low expression of olfactomedin 4 correlates with poor prognosis in smoking patients with non-small cell lung cancer.
    Su W; Luo L; Wu F; Lai Z; Li X; Xie Z; Tang Z; Yang Z; Liang R
    Hum Pathol; 2015 May; 46(5):732-8. PubMed ID: 25771901
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 13q deletion is linked to an adverse phenotype and poor prognosis in prostate cancer.
    Kluth M; Scherzai S; Büschek F; Fraune C; Möller K; Höflmayer D; Minner S; Göbel C; Möller-Koop C; Hinsch A; Neubauer E; Tsourlakis MC; Sauter G; Heinzer H; Graefen M; Wilczak W; Luebke AM; Burandt E; Steurer S; Schlomm T; Simon R
    Genes Chromosomes Cancer; 2018 Oct; 57(10):504-512. PubMed ID: 29923647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estrogen receptor-mediated miR-486-5p regulation of OLFM4 expression in ovarian cancer.
    Ma H; Tian T; Liang S; Liu X; Shen H; Xia M; Liu X; Zhang W; Wang L; Chen S; Yu L
    Oncotarget; 2016 Mar; 7(9):10594-605. PubMed ID: 26871282
    [TBL] [Abstract][Full Text] [Related]  

  • 18. OLFM4 is associated with lymph node metastasis and poor prognosis in patients with gastric cancer.
    Luo Z; Zhang Q; Zhao Z; Li B; Chen J; Wang Y
    J Cancer Res Clin Oncol; 2011 Nov; 137(11):1713-20. PubMed ID: 21904905
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genomic deletion of PTEN is associated with tumor progression and early PSA recurrence in ERG fusion-positive and fusion-negative prostate cancer.
    Krohn A; Diedler T; Burkhardt L; Mayer PS; De Silva C; Meyer-Kornblum M; Kötschau D; Tennstedt P; Huang J; Gerhäuser C; Mader M; Kurtz S; Sirma H; Saad F; Steuber T; Graefen M; Plass C; Sauter G; Simon R; Minner S; Schlomm T
    Am J Pathol; 2012 Aug; 181(2):401-12. PubMed ID: 22705054
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A quantitative proteomic approach of the different stages of colorectal cancer establishes OLFM4 as a new nonmetastatic tumor marker.
    Besson D; Pavageau AH; Valo I; Bourreau A; Bélanger A; Eymerit-Morin C; Moulière A; Chassevent A; Boisdron-Celle M; Morel A; Solassol J; Campone M; Gamelin E; Barré B; Coqueret O; Guette C
    Mol Cell Proteomics; 2011 Dec; 10(12):M111.009712. PubMed ID: 21986994
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.